Table 3.
Previous antimicrobial therapy within 1 month before SM bacteremia onset
| Antibiotics | Total (N = 55) |
Hemorrhagic pneumonia(N = 27) | Non-hemorrhagic pneumonia (N = 28) | P-value |
|---|---|---|---|---|
| Carbapenems, No. (%) | 46 (83.6) | 23 (85.2) | 23 (82.1) | 1.000 |
| aAnti-MRSAs, No. (%) | 38 (69.1) | 16 (59.3) | 22 (78.6) | 0.121 |
| Aminoglycoside, No. (%) | 5 (9.1) | 3 (11.1) | 2 (7.1) | 0.966 |
| Tigecycline, No. (%) | 23 (41.8) | 16 (59.3) | 7 (25.0) | 0.010 |
| Fluoroquinolones, No. (%) | 11 (20.0) | 6 (22.2) | 5 (17.9) | 0.686 |
| TMP-SMX, No. (%) | 3 (5.5) | 0 (0.0) | 3 (10.7) | 0.236 |
| Piperacillin/tazobactam, No. (%) | 15 (27.3) | 10 (37.0) | 5 (17.9) | 0.110 |
| Cefoperazone/sulbactam, No. (%) | 30 (54.5) | 14 (51.9) | 16 (57.1) | 0.694 |
| bAnti-fungles, No. (%) | 45 (81.8) | 20 (74.1) | 25 (89.3) | 0.266 |
aAnti-MRSAs included glycopeptides, linezolid, and daptomycin
bAnti-fungles included fluconazole, voriconazole, posaconazole, caspofungin and micafungin